Copyright
©The Author(s) 2017.
World J Hepatol. Jul 28, 2017; 9(21): 907-920
Published online Jul 28, 2017. doi: 10.4254/wjh.v9.i21.907
Published online Jul 28, 2017. doi: 10.4254/wjh.v9.i21.907
Drug | Molecular target | Study design | DCR | PFS | OS | TTP | Tolerabilty | Phase III study |
Lenvatinib[46] | VEGFR, FGFR, PDGFR,RET, KIT | Phase I/II (first line) | NR | NR | 18.7 mo | 12.8 mo | Favorable profile | Ongoing (E7080) |
Cabozantinib[47] | VEGFR-2, MET, RET | Phase II (second line) | 68% at 12 wk | 4.2 mo | NR | NR | Favorable profile | Ongoing (NCT01908426 – CELESTIAL) |
Tivantinib[48] | c-MET | Phase II (vs placebo, second line) | MET low NS MET high 50% vs 20% | NR | MET low NS MET high 7.2 mo vs 3.8 mo; P = 0.01 | MET low NS MET high 2.7 mo vs 1.4 mo; P = 0.04 | Severe neutropenia | Ongoing (NCT01755767) |
Apatinib[49] | VEGFR2 | Phase II (first line) | NR | NR | 9.7 mo | 4.2 mo | Favorable profile | Ongoing (NCT02329860) |
Refametinib[50] | MEK | Phase II (+ sorafenib) | 43%1 | NR | 290 d1 | 122 d1 | High incidence of 3/4 grade adverse events | NR |
Foretinib[51] | MET, RON, AXL, TIE-2, VEGFR | Phase I/II (first line) | 79% | NR | NR | 4.2 mo | Favorable profile | NR |
Tepotinib[52] | c-MET | Phase Ib/II (vs sorafenib, first line) - Ongoing | NR | NR | NR | NR | Favorable profile | NR |
Capmatinib[53] | c-MET | Phase I | NR | NR | NR | NR | Favorable profile | NR |
Golvantinib[54] | c-MET | Phase I/IIb (+ sorafenib) - Ongoing | NR | NR | NR | NR | Favorable profile | NR |
Emibetuzumab[55] | c-MET | Phase I (monotp vs emibetuzumab + erlotinib) | NR | NR | NR | NR | Favorable profile | NR |
LY2157299[56] | TGF-β | Phase II (second-line) | NR | NR | 36 wk2 | 12 wk2 | Favorable profile | Ongoing |
Pazopanib[57] | VEGFR1-3, PDGFRα-β, c-kit | Phase I | NR | NR | NR | NR | Favorable profile | NR |
Axitinib[58] | VEGFR1-3 | Phase II (vs placebo, second line) | NR | 3.6 mo vs 1.9 mo; P = 0.004 | 12.7 mo vs 9.7 mo; P = 0.287 | 3.7 mo vs 1.9 mo; P = 0.006 | Acceptable profile | NR |
- Citation: Le Grazie M, Biagini MR, Tarocchi M, Polvani S, Galli A. Chemotherapy for hepatocellular carcinoma: The present and the future. World J Hepatol 2017; 9(21): 907-920
- URL: https://www.wjgnet.com/1948-5182/full/v9/i21/907.htm
- DOI: https://dx.doi.org/10.4254/wjh.v9.i21.907